Last Updated : July 27, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete | ||
Adlyxine | lixisenatide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Admelog | Insulin lispro | Cancelled | ||||
Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
Adtralza | tralokinumab | atopic dermatitis (AD) | Do not reimburse | Active | ||
Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | |||
Advicor | Niacin/lovastatin | Hypercholesterolemia and mixed dyslipidemia | List | Complete | ||
Aermony RespiClick | fluticasone propionate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete |